Sources: U.S. Food and Drug Administration (FDA) Compounding and the FDA (503A & 503B guidance) FDA warning letters on unapproved peptide products National Institutes of Health (NIH) PubMed FDA has removed certain bulk drug substances that were placed on the category two list and has announced it will consult the Pharmacy Compounding Advisory Committee (PCAC) for potential future inclusion of BPC 157: Miracle Healing Peptide or Hidden Danger? Hims & Hers stock rises 14% as FDA schedules peptide compounding review BPC 157 + TB 500 Research Peptide Blend Laboratory Grade Intra Articular Injection Of Peptides For Joint Pain BPC 157 And TB 500 for Arthritis